Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Presentation

Neurological Complications After TAVR vs SAVRin Intermediate-Risk Patients

October 22, 2018

Presentation TCT 2018

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Presenter: Megan Coylewright

September 22, 2018

Presentation TCT 2018

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Presenter: Alfredo Trento

September 22, 2018

Presentation TCT 2018

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Presenter: Michael J. Mack

September 22, 2018

Presentation TCT 2018

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Presenter: Patrick T. O'Gara

September 22, 2018

Presentation TCT 2018

Counterpoint Volume Thresholds Distort Clinical Practice, Quality Metrics are the Priority and Have a Greater Impact on Outcomes

Presenter: Martin B. Leon

September 22, 2018

Presentation TCT 2018

Point Volume Threshold Increases are Needed to Assess Quality and Improve Clinical Outcomes

Presenter: Joseph E. Bavaria

September 22, 2018

Presentation TCT 2018

Opinion Concerns of TAVR Access for Underserved Populations

Presenter: Aaron Horne, Jr.

September 22, 2018

Presentation TCT 2018

Counterpoint Current and Future Demands Will Require TAVR Site Expansion

Presenter: Mark J. Russo

September 22, 2018

Presentation TCT 2018

Point Access Considerations Can be Managed Without Significant TAVR Site Expansion

Presenter: Carl L. Tommaso

September 22, 2018

Presentation TCT 2018

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Presenter: Charles J. Davidson, Jeffrey J. Popma, Matthew Summers

September 21, 2018

Presentation TCT 2018

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Presenter: Jose Armando Mangione

September 21, 2018

Presentation

Length of Stay and Discharge Disposition After TAVR and SAVR in the US

September 21, 2018

Presentation The Structural Heart Disease Summit 2018

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Presenter: Howard C. Herrmann, Allan Schwartz, Jonathan Afilalo

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Standards for SAVR and TAVR Bioprosthetic Valve Dysfunction and Failure: A Consensus Statement from EAPCI, ESC, and EACTS

Presenter: Michael J. Mack, Bernard Prendergast

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

TAVR and SAVR Therapy: Reconciling the Recent Society (ACC/AHA/ESC/EACTS) Guidelines With Clinical Practice Trends

Presenter: Daniel A Canos, Martin B. Leon, Vinod H. Thourani, Stephan Windecker

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Presenter: Eberhard Grube, Tamim Nazif, Alexandra J. Lansky

June 21, 2018

Presentation

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

May 11, 2018

Presentation

TAVR vs SAVR in Patients With Prior CABG

April 13, 2018

Advertisement

Neurological Complications After TAVR vs SAVRin Intermediate-Risk Patients

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Counterpoint Volume Thresholds Distort Clinical Practice, Quality Metrics are the Priority and Have a Greater Impact on Outcomes

Point Volume Threshold Increases are Needed to Assess Quality and Improve Clinical Outcomes

Opinion Concerns of TAVR Access for Underserved Populations

Counterpoint Current and Future Demands Will Require TAVR Site Expansion

Point Access Considerations Can be Managed Without Significant TAVR Site Expansion

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Length of Stay and Discharge Disposition After TAVR and SAVR in the US

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

New Standards for SAVR and TAVR Bioprosthetic Valve Dysfunction and Failure: A Consensus Statement from EAPCI, ESC, and EACTS

TAVR and SAVR Therapy: Reconciling the Recent Society (ACC/AHA/ESC/EACTS) Guidelines With Clinical Practice Trends

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

TAVR vs SAVR in Patients With Prior CABG

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content